Suppr超能文献

约旦乳腺癌的直接医疗成本:成本驱动因素和预测因素。

Direct medical costs of breast cancer in Jordan: cost drivers and predictors.

机构信息

Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, University of Jordan, Amman, Jordan.

Department of General Surgery, Faculty of Medicine, University of Jordan, Amman, Jordan.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):647-654. doi: 10.1080/14737167.2021.1859372. Epub 2020 Dec 22.

Abstract

: Breast cancer is the most common cancer amongst females in Jordan. The study aimed to estimate the total direct medical cost of breast cancer from a healthcare provider's perspective.: A retrospective cohort study was done to include all Jordanian females who were diagnosed with breast cancer at two leading public providers of cancer care in Jordan, Bashir Hospital and the University of Jordan Hospital. Data were extracted from the Jordan Cancer Registry (JCR) from 2011 to 2014 including demographic, clinical, and economic data of the patient.: A total of 877 and 665 patients were included in the first and second year after diagnosis, respectively. Costs increased in the advanced stages; costs for stages 0, I, II, III, and IV were Jordanian dinars)JD(6,749.94 ($9,517.42), JD 5,960.46 ($8,404.25), JD 8,003.58 ($11,285.05), JD 9,390.59 ($13,240.73), and JD 9,587.44 ($13,518.29), respectively. Treatment costs were the main cost driver across all stages.: This analysis offers insight into costs, cost drivers, and resources utilization incurred by breast cancer patients in Jordan. Two major hospitals in Jordan can play a key informative role in future cost-effectiveness of breast cancer screening and therapeutic treatments in the different stages of cancer.

摘要

: 乳腺癌是约旦女性中最常见的癌症。本研究旨在从医疗服务提供者的角度估计乳腺癌的总直接医疗费用。: 这是一项回顾性队列研究,纳入了在约旦两家主要癌症治疗机构——巴希尔医院和约旦大学医院被诊断为乳腺癌的所有约旦女性。数据来自 2011 年至 2014 年的约旦癌症登记处(JCR),包括患者的人口统计学、临床和经济数据。: 分别有 877 例和 665 例患者在诊断后第一年和第二年被纳入研究。成本随着疾病的进展而增加;0 期、I 期、II 期、III 期和 IV 期的成本分别为约旦第纳尔 6749.94 元(9517.42 美元)、5960.46 元(8404.25 美元)、8003.58 元(11285.05 美元)、9390.59 元(13240.73 美元)和 9587.44 元(13518.29 美元)。治疗费用是所有阶段的主要成本驱动因素。: 本分析提供了约旦乳腺癌患者的成本、成本驱动因素和资源利用情况的深入了解。约旦的两家主要医院可以在未来的乳腺癌筛查和不同癌症阶段的治疗成本效益方面发挥关键的信息作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验